Latest Conference Articles

Atezolizumab plus Chemotherapy Displays Efficacy, Tolerability in NSCLC with Untreated Brain Metastases

Atezolizumab plus carboplatin and pemetrexed yielded a favorable safety and efficacy profile in patients with advanced non-squamous non-small cell lung cancer with untreated brain metastases.

Elranatamab Alone or Plus Lenalidomide Shows Early Efficacy, Safety in Heavily Relapsed Myeloma

Elranatamab elicited encouraging responses with a manageable toxicity profile when used alone or in combination with lenalidomide in patients with relapsed/refractory multiple myeloma, with efficacy observed even in those who received prior BCMA-directed therapy or who were triple-class refractory, according to data from the phase 1 MagnetisMM-1 trial.

CAR T-Cell Therapies Show Promise Across Indolent Lymphomas

CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.

Rituximab-Bendamustine Combo Induces Superior Outcomes Over Other Regimens in Waldenström Macroglobulinemia

Treatment with fixed-duration rituximab plus the chemotherapy bendamustine was associated with more favorable outcomes than the triplet of dexamethasone, rituximab, and cyclophosphamide, as well as bortezomib, dexamethasone, and rituximab in patients with treatment-naïve Waldenström macroglobulinemia.

Cilta-Cel Continues to Yield Deep, Durable Response in Relapsed/Refractory Myeloma

A single dose of ciltacabtagene autoleucel continued to elicit early, deep, and durable responses and showcase a manageable safety profile in heavily pretreated patients with multiple myeloma.

Cilta-Cel Emerges as Potential CAR T-Cell Option in Relapsed/Refractory Multiple Myeloma

The CAR T-cell therapy ciltacabtagene autoleucel has emerged as a potentially durable treatment strategy for patients with relapsed/refractory multiple myeloma who have progressed on 1 to 3 prior lines of treatment and are refractory to lenalidomide.

Ide-Cel Maintains Clinical Activity With Long-Term Follow-Up in Relapsed/Refractory Multiple Myeloma

Idecabtagene vicleucel continued to elicit frequent, deep, and durable responses among patients with heavily pretreated relapsed/refractory multiple myeloma irrespective of whether patients received 3 or at least 4 prior therapies.

Talquetamab Continues to Impress in Relapsed/Refractory Multiple Myeloma

Talquetamab, an off-the-shelf T-cell redirecting, GP3C5D-targeting agent, has continued to show promising clinical activity in patients with relapsed/refractory multiple myeloma, especially when given at the recommended phase 2 dose of 405 µg/kg weekly in subcutaneous formulation.

Challenges Remain in Treatment of Accelerated Phase Myeloproliferative Neoplasms

Treating patients with accelerated phase myeloproliferative neoplasm is an ongoing therapeutic challenge, due to the lack of standard treatment approaches, according to an expert.

Dr. Sanchorawala on the Impact of Depth of Renal and Cardiac Response on Survival in AL Amyloidosis

Vaishali Sanchorawala, MD, discusses the impact of renal and cardiac response on survival in patients with light chain amyloidosis. 

Dr. Verstovsek Discusses Research Efforts in Myelofibrosis-Related Anemia

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

TP53 and IGHV Status Retain Utility as Prognostic Markers in CLL

Historical prognostic markers for chemoimmunotherapy have largely lost their clinically relevance in the context of targeted therapies for patients with chronic lymphocytic leukemia; however, IGHV and TP53 mutational status remain important predictive markers of response, now for novel treatments.

Lurbinectedin/Doxorubicin Misses OS End Point in Relapsed SCLC, But Shows Superior Safety Vs SOC

The combination of lurbinectedin and doxorubicin produced comparable efficacy to that of standard-of-care vincristine, cyclophosphamide, and doxorubicin or topotecan in patients with relapsed small cell lung cancer, missing the primary end point of the phase 3 ATLANTIS trial.

Noncovalent BTK Inhibitors, CAR T-Cell Therapy Generate Excitement in CLL

Sitting at the forefront of clinical development, pirtobrutinib and lisocabtagene maraleucel have generated significant enthusiasm in chronic lymphocytic leukemia.

Controlling Infections Could Be Key to Improving Survival in CLL

Patients with chronic lymphocytic leukemia are at an increased risk for infection whether they are in the premalignant state of monoclonal B lymphocytosis, during active surveillance for those are treatment naïve, or are on active treatment.

Higher Rates of Respiratory Disorders Retrospectively Identified in Polycythemia Vera

Estimated 4-year mortality rates were greater than 10% in patients with polycythemia vera and vascular complications led to approximately one-third of these deaths, according to a retrospective analysis of the prospective REVEAL trial (NCT02252159) presented during the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting.

Adjuvant Atezolizumab Improves DFS in Early-Stage NSCLC Across Most Disease Stages and Prior Therapies

Adjuvant atezolizumab improved disease-free survival over best supportive care in patients with PD-L1–positive, stage II to IIIA non–small cell lung cancer, with benefit observed across most subgroups analyzed, according to data from an exploratory analysis of the phase 3 IMpower010 trial.

Pirtobrutinib Shows Impressive Efficacy in Previously Treated CLL/SLL

Pirtobrutinib, showcased promising efficacy signals across dose levels in previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

The effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.

Treatment Strategies Utilizing New Agents and Existing Therapies Can Improve Outcomes in Myelofibrosis

Various phase 2 and 3 studies are currently underway utilizing both new and existing treatments in an effort to improve outcomes for patients with myelofibrosis.

Frontline Durvalumab/Chemo, With or Without Tremelimumab, Improves PFS in Advanced NSCLC

The first-line combination of durvalumab and chemotherapy, with or without tremelimumab, led to a statistically significant improvement in progression-free survival compared with chemotherapy alone in patients with metastatic non–small cell lung cancer, according to data from the phase 3 POSEIDON trial.

Data Confirms Efficacy of Fixed-Volume Isatuximab-Based Combination for Newly Diagnosed Multiple Myeloma

The safety and efficacy of the quadruplet regimen of fixed-dose isatuximab-irfcc in combination with bortezomib, lenalidomide, and dexamethasone were confirmed for patients with newly diagnosed multiple myeloma with no immediate intent for transplant.

Future of PV Treatments Centers Around More Tailored Approaches

Future treatment approaches for patients with polycythemia vera (PV) should center around adapting therapy using the available criteria, and eventually finding new targets.

MRD Could Play Role in Predicting Post-ASCT Outcomes in Myeloma

For patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease may be a powerful predictor of outcomes.

Daratumumab Plus Combination Therapy May Be New Standard of Care for Newly Diagnosed Multiple Myeloma

Older patients with newly diagnosed multiple myeloma who are ineligible for chemotherapy or transplant may derive a greater benefit when treated with daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone.

Venetoclax Plus FLAG-IDA Elicits High and Durable Responses in Newly Diagnosed AML

The addition of venetoclax to fludarabine, cytarabine, idarubicin and G-CSF resulted in high complete response rates and enables a high consolidative allogeneic transplantation rate in patients with newly diagnosed acute myeloid leukemia.

Dr. Coombs on the Efficacy Results of the BRUIN Study With Pirtobrutinib in CLL

Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.

Iberdomide Combination Shows Promise and Tolerability in Multiple Myeloma

Iberdomide combined with dexamethasone and either daratumumab, bortezomib, or carfilzomib showed efficacy and tolerability in patients with relapsed or refractory multiple myeloma.

Phase 2 Data Signal a Potential Role for Neoadjuvant Osimertinib in EGFR-mutant NSCLC

Updated data from a phase 2 trial presented at the 2021 World Conference on Lung Cancer showed that neoadjuvant osimertinib induced a pathologic complete response among patients with surgically resectable EGFR-mutant non–small cell lung cancer.

Mobocertinib Elicits Efficacy in Advanced EGFR Exon 20 Insertion+ NSCLC Regardless of Prior Immunotherapy

Mobocertinib demonstrated clinical activity in previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer whether or not they received a prior PD-1/PD-L1 inhibitor.